Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

The cystic fibrosis (cf) therapeutics market size has grown rapidly in recent years. It will grow from $6.91 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth observed in the historic period can be attributed to several factors, including advancements in targeted therapies, a deeper understanding of cystic fibrosis (CF) genetics, increased patient advocacy and awareness, government support for research initiatives, and incentives for rare disease research, such as orphan drug designations. These elements collectively contributed to the progress and development of therapeutics for cystic fibrosis during the historical period.

The cystic fibrosis (cf) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The anticipated growth in the forecast period can be attributed to factors such as the rise in the cystic fibrosis (CF) patient population, regulatory approvals for novel therapies, a focus on personalized medicine, increased investment in biomarker research, expanded newborn screening programs, and healthcare policy support. Major trends expected in the forecast period include the expansion of CFTR modulators, the utilization of gene editing technologies, early intervention strategies, improved diagnostic techniques, the integration of telehealth and remote monitoring, the digitalization of healthcare, and advancements in chronic disease management.

The projected increase in the population affected by cystic fibrosis (CF) is set to be a driving force behind the expansion of the cystic fibrosis therapeutics market. CF, an inherited condition impacting the lungs, digestive system, and other organs, necessitates therapeutic interventions to thin lung mucus, making it easier to expel. As the number of individuals suffering from cystic fibrosis rises, the demand for effective CF therapeutics is expected to soar. An illustrative example is a report released by The Cystic Fibrosis (CF) Foundation in July 2022, revealing a surge in CF cases, with almost 40,000 affected individuals in the United States and over 105,000 diagnosed worldwide. This escalation in CF patients is a significant driving factor fueling the cystic fibrosis therapeutics market growth.

The burgeoning emphasis on personalized medicine and targeted therapies is poised to drive the cystic fibrosis therapeutics market forward. Personalized medicine involves tailoring medical care based on patients' unique genetic makeup, proteins, and other biological factors, enabling precise and individualized treatments. This approach aids in comprehending the intricate genetic mutations underlying CF, paving the way for customized treatment plans aligned with each patient's distinct genetic profile. Notably, The Scope and Significance of Progress in 2022 report by the Personalized Medicine Coalition highlighted the US Food and Drug Administration's approval of 12 personalized medicines in 2022, constituting approximately 34% of all newly approved therapeutic molecular entities. This growing focus on personalized medicine and targeted therapies is a driving force behind the expansion of the cystic fibrosis therapeutics market.

Product innovation stands out as a pivotal trend gaining traction within the cystic fibrosis therapeutics market. Leading companies in this sector are dedicating efforts to developing novel products to gain a competitive edge. For instance, Chiesi USA introduced Bronchitol (mannitol) powder in March 2021 - a groundbreaking inhalation powder designed for cystic fibrosis patients. Distinguished as the 'First and Only' dry-powder inhaled mucoactive agent, Bronchitol offers unique features such as portability, no refrigeration requirement, and reduced cleaning frequency, setting a new standard for convenience and efficacy in CF therapeutic interventions. This product innovation signifies a growing trend towards more accessible and effective treatments within the cystic fibrosis therapeutics market.

Key players within the cystic fibrosis (CF) therapeutics market are actively directing their efforts towards strategic investments aimed at expanding their presence and fortifying their market positions. Strategic investment in medical research encompasses a deliberate allocation of resources, expertise, and funding into scientific research endeavors with the primary objectives of advancing medical understanding, developing innovative treatments, and refining healthcare protocols. An exemplary instance of such strategic investment occurred in January 2023 when the Cystic Fibrosis Foundation (CF Foundation), a US-based non-profit organization dedicated to supporting diverse research initiatives for CF cure, announced a significant investment of up to $15 million in ReCode Therapeutics. ReCode, a US-based clinical-stage genetic medicines and biotechnology company, specializes in employing advanced delivery mechanisms to drive the next wave of messenger ribonucleic acid (mRNA) and gene correction therapeutics. This substantial investment is intended to facilitate the development of ReCode's inhaled mRNA-based therapeutic tailored for individuals with cystic fibrosis (CF), particularly those with genotypes unresponsive to approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

In November 2021, the CF Foundation embarked on a collaborative effort with Flagship Pioneering, a US-based life sciences venture capital company, under the Pioneering Medicines initiative to propel the advancement of genetically based treatments for cystic fibrosis. This partnership, part of the Foundation's Path to a Cure research agenda, entails a planned investment of up to $110 million, with an initial commitment of $20 million. The Pioneering Medicines initiative will amalgamate technologies from various flagship-founded enterprises to establish a distinct entity dedicated to exploring novel approaches to treating cystic fibrosis. These strategic investments underscore the commitment of major stakeholders in the cystic fibrosis therapeutics market to foster innovation, drive research, and pioneer new treatments for individuals affected by this condition.

Major companies operating in the cystic fibrosis (cf) therapeutics market report are Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Vivus, Pharmaxis, Genentech, Bayer AG, Eli Lilly and Company, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd. , Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals , Translate Bio Inc, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc. , Zambon S.p.A.

North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cystic fibrosis (cf) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary drug classes for CF therapeutics include pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Pancreatic enzyme supplements contain pancreatin or pancrelipase, a combination of lipase, amylase, and protease, produced by the pancreas. These supplements can be administered orally or through inhalation. The treatment methods for cystic fibrosis involve a combination of medications and devices to manage the condition effectively.

The cystic fibrosis therapeutics market research report is one of a series of new reports that provides cystic fibrosis therapeutics market statistics, including cystic fibrosis therapeutics industry global market size, regional shares, competitors with a cystic fibrosis therapeutics market share, detailed cystic fibrosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis therapeutics industry. This cystic fibrosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.